Julia Tsai

Julia Tsai, Ph.D., is the senior vice president of Clinical Development and Medical Affairs at Ovid, where she develops, leads, and drives the clinical development strategy of Ovid’s clinical pipeline. She joined Ovid in 2020 as vice president of Clinical Development-Epilepsies and led the transition of soticlestat from Phase 2 to 3 in a joint development program with Takeda. Prior to joining Ovid, Dr. Tsai held roles of increasing responsibility through her tenure at Marinus Pharmaceuticals (NASDAQ: MRNS) and was part of the founding clinical development team, which led the strategic growth of the company from inception through its IPO and beyond. She left Marinus as the vice president of Clinical Development, head of the epilepsy franchise, which included experience in rare and general epilepsy programs.

Dr. Tsai brings more than 17 years of central nervous system development and regulatory experience from multiple indications within neurology and psychiatry, including: resistant epilepsy, post-traumatic stress disorder and orphan diseases (behaviors in Fragile X syndrome, West syndrome, Status Epilepticus, CDKL5 Deficiency Disorder, PCDH19 female-related Epilepsies, Dravet syndrome, Lennox Gastaut syndrome and Dup15q syndrome).

Dr. Tsai holds a Doctorate in Physiology and Biophysics from the Neuroscience and Physiology program at New York University School of Medicine and a Bachelor of Arts in Psychology from Cornell University.